Frost & Sullivan 2026 Blue Book Charts Hong Kong 18A Biotech Sector's Shift Toward Value-Driven Growth
核心洞察
Frost & Sullivan (搜索), with TradeGo (搜索), LeadLeo (搜索) and CCXGF (搜索), released the 2026 Blue Book on the Hong Kong Stock Exchange (搜索) Chapter 18A biotech sector on September 3, 2026.
Nearly 93 biotech companies had listed under the 18A framework as of June 2026, spanning small molecules, antibodies, vaccines, nucleic-acid medicines, CGT and medical devices.
China-origin antibody out-licensing deals grew from 3 to 56 between 2019 and 2025, with disclosed value rising from USD 0.7 billion to USD 65.0 billion.
Frost & Sullivan (搜索), in partnership with TradeGo (搜索), LeadLeo (搜索) and CCXGF (搜索) (China Chengxin Green Finance Technology (Beijing) Ltd.), has unveiled the 2026 Blue Book on the Development of Hong Kong Stock Exchange (搜索) 18A Biotech Sector, delivering an in-depth panorama of the Hong Kong 18A biotech ecosystem, capital market cycles, innovative drug R&D breakthroughs, enterprise commercialization progress and global expansion trends. The report, released on September 3, 2026, serves as a critical reference for industry practitioners, investors, research institutions and regulatory stakeholders seeking to grasp industrial dynamics and make strategic decisions.
Since the launch of the Hong Kong Stock Exchange (搜索)'s Chapter 18A listing rules in 2018, Hong Kong has built a vital financing hub for unprofitable biotech firms from Greater China. As of June 2026, nearly 93 biotech companies have gone public under the 18A framework, covering small-molecule drugs, antibody therapeutics, vaccines, nucleic-acid medicines, peptides, cell and gene therapy (CGT), in-vitro diagnostics (IVD), surgical robots, medical devices and other high-growth innovation tracks. A growing number of enterprises have completed clinical development and achieved product commercialization, marking the sector's transition from pure R&D-driven speculation toward value-oriented industrial growth.
Capital Market Cycle Reset and Valuation Normalization
Global biotech capital markets have passed through distinct development phases: an upward boom from 2016 to 2020, a historical peak in 2021, a deep correction during 2022 to 2023, and an ongoing recovery from 2024 to 2026. Hong Kong 18A stocks witnessed a heavy correction between 2021 and 2022, with market capitalization evaporating by more than 60%. Entering 2023, the sector remained at low valuation troughs.
Driven by southbound capital inflows and robust overseas business development (BD) transaction performance, the sector staged a remarkable market rebound. From mid-2024 to July 2025, the index surged over 71%, and climbed 82% across full-year 2025, with market capitalization recovering to 50–60% of its 2021 peak level.
Market participants have become increasingly rational, according to the Blue Book. Investment focus has shifted away from pure concept speculation toward clinical milestone delivery, product commercialization capacity, real-world sales performance and sustainable profitability. The industry has completed its cycle-wide shake-out, with capital firmly anchoring on fundamental business performance.
Diversified Innovation Pipeline Matures Across Multiple Tracks
Chinese biotech innovation capability continues to advance, with clinical declaration volume maintaining high activity across therapeutic segments.
In antibody therapeutics, monoclonal antibodies remain the market cornerstone, while bispecific antibodies and antibody-drug conjugates (ADCs) act as core growth engines. From 2019 to 2025, China-origin antibody-related out-licensing transactions jumped from 3 to 56 deals, with aggregate disclosed transaction value rocketing from USD 0.7 billion to USD 65.0 billion. The asset portfolio has upgraded from conventional monoclonal antibodies toward high-value bispecific antibodies and ADC candidates.
Small-molecule drugs are seeing momentum in cutting-edge modalities including PROTAC, molecular glues and allosteric modulators, with domestic new-drug approvals continuing to rise. Vaccine R&D spans mRNA, recombinant protein and other next-generation platforms, as domestic players accelerate product iteration and global market access. Nucleic-acid therapeutics are expanding rapidly across both siRNA/ASO small-nucleic-acid and mRNA drug pipelines, with upstream industrial-chain localization gathering pace. In cell and gene therapy, CAR-T and other cell therapy products are coming to market, with advancements covering vector development, CDMO capacity build-up and diversified payment-model exploration. Peptide medicines are being propelled by GLP-1-class agents, which fuel market expansion and bring new opportunities for domestic R&D and industrial translation.
License-Out Emerges as Core Growth Driver
Cross-border BD transactions have become a signature feature of China's biotech industry. From 2021 to the first half of 2026, the volume of domestic biotech BD out-licensing transactions stayed at a high level. In 2025, China's biotech BD transaction value hit USD 143.14 billion. Apart from classic license-out deals, the NewCo collaboration model is gaining increasing adoption as an innovative international cooperation vehicle.
Out-licensed assets are no longer limited to traditional small-molecule medicines. ADCs, bispecific antibodies, nucleic-acid drugs and other frontier innovative assets account for a larger share of deals. Chinese biotech companies are advancing multi-regional global clinical trials, registering products with the FDA and EMA, and steadily building worldwide commercial capabilities.
AI and Synthetic Biology Reshape Drug Discovery
AI is penetrating the full drug-development chain, covering target identification, protein and antibody design, generative molecular optimization and clinical-trial design. According to the Blue Book, AI shortens R&D cycles, cuts costs and lifts clinical success rates, evolving into a core competitive moat for biotech organizations. Synthetic biology further unlocks possibilities for the engineering of next-generation biomedicine products.
From Financing Tool to Global Resource-Integration Platform
18A biotech enterprises have matured in their capital-market mindset. The listing function has upgraded from pure fundraising toward global resource integration, with more firms pushing commercial capability forward in early development phases. Operational priorities are shifting from short-term valuation management to building long-term operational strength, and capital markets are gradually forming a long-term value-driven pricing logic.
The Blue Book also profiles representative 18A-listed biotech enterprises across vaccine, endocrine therapy, oncology innovative drug, antibody, nucleic-acid, medical device and surgical-robot segments, showcasing their technology platforms, R&D pipelines, key clinical milestones and commercial progress.